BENGALURU (June 15): Anglo-Swedish drug maker AstraZeneca said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic Covid-19 in people recently exposed to the novel coronavirus.The company said…